Should you take TMG with NMN?
Reviewed 17 sourcesPublished by PepVault
NMN does spend methyl groups, but in trials homocysteine barely moved. What TMG does in people, the cholesterol trade-off, and the blood test that decides it.

- Last reviewed
- Sources
- 17
- Questions
- 6
- Compounds
- 3
The short answer
Usually not, unless a blood test says so. NMN does cost methyl groups: the body clears spare nicotinamide by methylating it. But in trials, homocysteine barely moved: up 1.7 µmol/L on 3,000 mg of NR a day, and no spike after 1,000 mg of NMN. TMG lowers homocysteine by 1 to 2 µmol/L and, at 4 g a day or more, nudges cholesterol up.
Evidence: Small human studies of the methyl cost (single-dose and 14- to 30-day trials of nicotinamide, NR and NMN, up to 65 people each, only one with an NMN arm reporting homocysteine); randomized trials and meta-analyses for betaine's homocysteine and cholesterol effects; an FDA drug label for homocystinuria. No published trial has tested TMG with NMN.

Does NMN use up your methyl groups?
Yes, some, and you can see it in the blood. NMN (nicotinamide mononucleotide) is a form of vitamin B3 that cells build into NAD+, the coenzyme they use to turn food into energy. When enzymes such as sirtuins and PARPs burn NAD+, they release nicotinamide. The body recycles most of it; the spare is cleared by an enzyme called NNMT, which sticks a methyl group (one carbon with three hydrogens) onto it. The tagged molecule, methylnicotinamide, is broken down to two end products, 2PY and 4PY, and leaves in the urine2.
That methyl group comes from SAMe (S-adenosylmethionine), the body's main methyl donor, the same pool that tags DNA and clears stress hormones such as adrenaline25. Once SAMe gives up its methyl, what is left becomes homocysteine, an amino acid that has to be recycled back to methionine. Two routes do that: one runs on folate and vitamin B12, the other on betaine, which is TMG (trimethylglycine)214. So the idea behind the pairing is plain chemistry: NMN sends methyl groups out, TMG brings them back.
The first step is proven in people. Ten healthy Japanese men took single doses of 100, 250 and 500 mg of NMN, and plasma 2PY and 4PY rose with every step up in dose1. The question that matters is the next one: does that cost show up as higher homocysteine or less methylation?
Animal note: in rats fed nicotinamide at 1 or 4 g per kg of food for 8 weeks, blood betaine fell and liver DNA methylation dropped17. Those are far larger amounts for their body size than a capsule, and the result is in rats, not people.

Does NMN or NR raise homocysteine in people?
Plain nicotinamide does, quickly. NR and NMN, at the amounts people take, barely move it. These are the human studies that measured it, as of November 2026:
| Study | Who, how long | Daily amount | Homocysteine and methyl markers |
|---|---|---|---|
| Sun 20125 | 46 adults, one dose, 5 hours | Nicotinamide 100 mg | Homocysteine up in people with normal blood pressure; betaine, a methyl donor, down in everyone |
| Christen 20264 | 65 healthy adults, 14 days, open-label | Nicotinamide 500 mg; NR 1,000 mg; NMN 1,000 mg | After a nicotinamide dose, the homocysteine rise (area under the curve) was more than 8 times placebo's; no such spike on NR or NMN. Over the 14 days, levels held slightly higher than placebo on NR and nicotinamide; NMN's difference was not significant |
| NADPARK, via Gaare 20232 | 29 people with Parkinson disease from a placebo-controlled trial, 30 days | NR 1,000 mg | SAMe, its by-product SAH and homocysteine in blood cells and muscle unchanged; DNA methylation unchanged, including in MTHFR gene carriers |
| NR-SAFE, Berven 20233 | 20 people with Parkinson disease, 4 weeks, placebo-controlled | NR 3,000 mg | Serum homocysteine +1.66 µmol/L at the last visit; the rise came by day 3 and then held. Placebo unchanged. Whole-blood homocysteine, SAMe and SAH unchanged; whole-blood betaine fell slightly; B12 and folate unchanged |
| Garg 19996 | 52 people with leg-artery disease, 48 weeks | Niacin (nicotinic acid), raised from 100 to 1,000 mg, then the trial dose | Up 17% while the dose rose to 1,000 mg; 55% above baseline at 18 weeks |
The pattern is consistent. A straight dose of nicotinamide floods the clearance route at once, and homocysteine jumps for a few hours45. NR and NMN reach the body more slowly, and the trial's authors propose that gut bacteria handle part of each first4; the trials found no spike on either, no fall in SAMe and no change in DNA methylation over 30 days234. Even at three times the usual NR amount, the rise was 1.66 µmol/L, and it stopped growing after day 33. Niacin, the high-dose cholesterol drug form of B3, is the case with a large and lasting rise6.
One gap stands out. No trial of NMN alone has published a homocysteine result; the NMN arm of the 14-day head-to-head trial is the only published number4. A 29-day trial of 400 mg of NMN a day in 24 healthy adults, sponsored by Seneque, listed homocysteine as an outcome and was completed in March 2023; as of November 2026 its registry record shows no results16. In that head-to-head trial, NMN looked like NR4.
What does TMG do in people?
TMG lowers homocysteine, reliably and modestly, and at the higher amounts it raises cholesterol. Food already supplies about 0.5 to 2 g of betaine a day, from foods such as beets, spinach, cereals and seafood714. The trials, in healthy adults unless noted:
| Study | Daily amount, how long | Homocysteine | Cholesterol |
|---|---|---|---|
| Olthof 20037 | 1.5, 3 or 6 g, 6 weeks, 76 adults | 12%, 15% and 20% lower than placebo | Not the endpoint here |
| Steenge 20038 | 6 g, 6 weeks, adults with mildly high homocysteine | 1.8 µmol/L lower than placebo | Not the endpoint here |
| Schwab 200211 | 6 g, 12 weeks, 42 adults with obesity on a diet | Lower than control | Total and LDL cholesterol higher than control |
| Olthof 2005, 3 trials pooled10 | 6 g, 6 weeks, 151 adults | Lowered (the trials' aim) | LDL +0.36 mmol/L (about 14 mg/dL), triglycerides +0.14 mmol/L; lower amounts raised LDL too, not significantly |
| McRae 2013, 5 trials9 | 4 g or more, 6 to 24 weeks | -1.23 µmol/L | Not pooled |
| Zawieja 2021, 6 trials12 | 4 g or more, 6 to 24 weeks | Not pooled | Total +0.34 mmol/L (about 13 mg/dL); LDL, HDL and triglycerides not significant |
| Ashtary-Larky 2022, pooled13 | Various amounts | -1.30 µmol/L | Total +14.1 mg/dL, LDL +10.3 mg/dL; a subgroup suggested under 4 g a day lowers homocysteine without the lipid rise |
Two findings matter most for the NMN question. The drop is small outside the rare inherited diseases: about 1 to 2 µmol/L, even in adults whose homocysteine was mildly high8913, roughly the size of the rise NR-SAFE saw at 3,000 mg of NR3. And the amount decides the trade: at 6 g, LDL rose within 2 weeks10, while a subgroup analysis in the 2022 pooled review suggested that amounts under 4 g a day lower homocysteine without moving lipids13. The Wageningen team that ran the 6 g trials concluded that folic acid, which lowered homocysteine without touching lipids, remains the preferred way to lower it10.
Commonly reported: nothing felt when TMG is added beside NMN, either way; at multi-gram amounts some notice a mild stomach upset, which matches the drug label's most common effects, nausea and stomach distress14.
What is betaine approved for?
Betaine anhydrous is an FDA-approved drug, Cystadane, for homocystinuria: a group of rare inherited conditions in which homocysteine runs many times above normal. The label, last updated April 27, 2026 on DailyMed, calls it a methylating agent that donates a methyl group to turn homocysteine back into methionine14.
The label's dose for adults and children from age 3 is 6 g a day, given as 3 g twice daily, raised as needed by the homocysteine result; some patients have needed up to 20 g14. It warns that in one type, CBS deficiency, betaine can push methionine higher and brain swelling has been reported, a warning about that disease14. The approval shows how well betaine works where homocysteine is very high. It says nothing about adding TMG to NMN in healthy people, which no published trial has tested.
How do you decide if you need TMG with NMN?
Let a blood test decide, not a ratio. The popular 1:1 NMN-to-TMG rule has no trial behind it; homocysteine is a cheap, routine test, and it answers the question for you. One way to run it:
- Get a baseline homocysteine and lipid panel before you start NMN or change the amount.
- Keep NMN at one daily amount; the trials that measured methyl markers held the amount steady23.
- Retest after 6 to 8 weeks. NR-SAFE's rise had appeared by day 33, and the TMG trials read homocysteine at 6 weeks78.
- Compare the number with the last one and with your lab's range, not with a supplement maker's band.
- If homocysteine rose, take the result to your clinician, who can look at folate and B12, the other recycling route, alongside it. If you add TMG, retest LDL too, since 4 g or more a day raised cholesterol in trials1213.
PepVault keeps NMN and TMG in one protocol, and each can carry its own dose-time reminder, so the weeks between two blood tests are logged rather than remembered. Set reminders in PepVault
- If you take a statin or another lipid drug, whether TMG fits is your prescriber's call, since it moves cholesterol the other way12.
In PepVault's bloodwork section, add homocysteine as your own marker beside the built-in total cholesterol and LDL, so each panel is saved with its test date. Log it in PepVault
The first trial built to compare the pair is now running. At Concordia University Chicago, 40 healthy adults aged 60 to 80 are split into two groups: one takes an NMN-with-TMG product, the other NMN alone, each for 4 weeks against a 4-week placebo period in a double-blind crossover trial (each person has both periods). It started in February 2026 and is due to finish in January 202715. Its main outcome is exercise tolerance; blood NAD+ is a secondary outcome, and fasting homocysteine is listed among its other outcomes, so it may give the first homocysteine numbers for NMN with and without TMG.
When to get help A homocysteine result above your lab's range, or numbness, tingling or memory changes, which can come with low B12, is a reason to see your clinician.
Where to read more
- The library pages: pepvault.app/peptides/nmn, /peptides/tmg-betaine (and its stacks page, /peptides/tmg-betaine/stacks) and /peptides/nicotinamide-riboside, and the longevity hub at pepvault.app/longevity.
- Which precursor raises NAD+ the most is in our guide NAD+ vs NMN vs NR; what a finger-prick NAD+ number does and does not tell you is in Do NAD+ blood tests mean anything?; the short library comparison is at pepvault.app/peptides/compare/nad-vs-nmn.
- Study pages: pepvault.app/research/nmn-irie-2020 (the 2PY and 4PY rise) and /research/nad-christen-2026 (the head-to-head trial).
- Placebo, open-label, crossover trial, randomized controlled trial and meta-analysis are explained at pepvault.app/glossary/placebo, /glossary/open-label, /glossary/crossover-trial, /glossary/randomized-controlled-trial and /glossary/meta-analysis.
Sources
- Irie J et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr J. 2020. PubMed 31685720
- Gaare JJ et al. Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. iScience. 2023. PubMed 36936793
- Berven H et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun. 2023. PubMed 38016950
- Christen S et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026. PubMed 41540253
- Sun WP et al. Excess nicotinamide inhibits methylation-mediated degradation of catecholamines in normotensives and hypertensives. Hypertens Res. 2012. PubMed 21918528
- Garg R et al. Niacin treatment increases plasma homocyst(e)ine levels. Am Heart J. 1999. PubMed 10577438
- Olthof MR et al. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr. 2003. PubMed 14652361
- Steenge GR et al. Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr. 2003. PubMed 12730412
- McRae MP. Betaine supplementation decreases plasma homocysteine in healthy adult participants: a meta-analysis. J Chiropr Med. 2013. PubMed 23997720
- Olthof MR et al. Effect of homocysteine-lowering nutrients on blood lipids: results from four randomised, placebo-controlled studies in healthy humans. PLoS Med. 2005. PubMed 15916468
- Schwab U et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr. 2002. PubMed 12399266
- Zawieja EE et al. Betaine supplementation moderately increases total cholesterol levels: a systematic review and meta-analysis. J Diet Suppl. 2021. PubMed 31809615
- Ashtary-Larky D et al. Effects of betaine supplementation on cardiovascular markers: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022. PubMed 33764214
- CYSTADANE (betaine anhydrous for oral solution) prescribing information. Recordati Rare Diseases. DailyMed, SPL version 7, Apr 27, 2026. dailymed.nlm.nih.gov
- NCT07144527. Nicotinamide mononucleotide supplementation for exercise tolerance improvement in healthy older adults (NMN with TMG vs NMN vs placebo). ClinicalTrials.gov, last updated Oct 7, 2026. clinicaltrials.gov
- NCT04910061. Safety and pharmacokinetics of nicotinamide mononucleotide (NMN, 400 mg) over 29 days in healthy adults. Seneque SA. ClinicalTrials.gov, completed Mar 2023, no results posted. clinicaltrials.gov
- Li D et al. Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. Br J Nutr. 2013. PubMed 23768418
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.